Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion

Novartis (NVS) has entered into a global license and collaboration agreement with PTC Therapeutics (PTCT) for the latter’s Huntington's disease candidate to strengthen NVS’ neuroscience pipeline.NVS also announced a collaboration with Olema Pharmaceuticals, Inc. (OLMA) for a breast cancer drug.Year to date, shares of Novartis have risen 3.8% compared with the industry’s growth of 8.9%.Image Source: Zacks Investment ResearchNVS’ Licensing Deal With PTCTNovartis will in-license PTC Therapeutics’ PTC518.  The ...